1-8 of 8
Jamie Brower
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Free
Veronika Bachanova, Qing Cao, Marie Hu, Supriya Gupta, Miguel-Angel Perales, Olalekan Oluwole, Richard Maziarz, Joseph McGuirk, Andy Chen, Stephen J. Schuster, Gunjan Shah, Anthony Hunter, Jamie Brower, David Porter, Peter Riedell
Journal: Blood
Blood (2025) 146 (Supplement 1): 400.
https://doi.org/10.1182/blood-2025-400
Published: 2025
Journal Articles

Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium

Free
Alexandra Rojek, Alyssa Gibson, Marina Gomez-Llobell, Miguel-Angel Perales, Joseph McGuirk, Stephen Schuster, David Porter, Jamie Brower, Hanan Alharthy, Sairah Ahmed, Richard Maziarz, Veronika Bachanova, Olalekan Oluwole, Anthony Hunter, Peter Riedell
Journal: Blood
Blood (2025) 146 (Supplement 1): 2707.
https://doi.org/10.1182/blood-2025-2707
Published: 2025
Journal Articles

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Free
Alexandra E. Rojek, Nausheen Ahmed, Marina Gomez Llobell, Sairah Ahmed, Marie Hu, Monica Mead, Andy Chen, Vivek Patel, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Olalekan O. Oluwole, Michael R Bishop, David L. Porter, Miguel Angel Perales, Joseph P. McGuirk, Peter A. Riedell, Daniel J. Landsburg
Journal: Blood
Blood (2024) 144 (Supplement 1): 4503.
https://doi.org/10.1182/blood-2024-198153
Published: 2024
Journal Articles

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

Free
William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Peter A. Riedell, Miguel-Angel Perales, Richard T Maziarz, Jamie Brower, Gunjan L. Shah, Andy Chen, Olalekan O. Oluwole, Stephen J Schuster, Michael R. Bishop, Joseph P McGuirk, Nausheen Ahmed
Journal: Blood
Blood (2023) 142 (Supplement 1): 4887.
https://doi.org/10.1182/blood-2023-182837
Published: 2023
Journal Articles

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Free
Peter A Riedell, Connor Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J Schuster, Andy Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter
Journal: Blood
Blood (2023) 142 (Supplement 1): 617.
https://doi.org/10.1182/blood-2023-184862
Published: 2023
Journal Articles

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Free
Michael Scordo, Jessica R. Flynn, Sean M. Devlin, Mithat Gonen, Allison Parascondola, Ana Alarcon Tomas, Roni Shouval, Jamie Brower, David L. Porter, Stephen J. Schuster, Veronika Bachanova, Joseph E. Maakaron, Richard T. Maziarz, Loretta J. Nastoupil, Joseph P. McGuirk, Olalekan O. Oluwole, Andrew Ip, Lori A. Leslie, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood
Blood (2022) 140 (Supplement 1): 1588–1591.
https://doi.org/10.1182/blood-2022-164674
Published: 2022
Journal Articles

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Free
Peter A. Riedell, Jamie Brower, Loretta Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Joseph P. McGuirk, Veronika Bachanova, Wei-Ting Hwang, Stephen J. Schuster, Michael R. Bishop, David L. Porter
Journal: Blood
Blood (2021) 138 (Supplement 1): 2512.
https://doi.org/10.1182/blood-2021-151971
Published: 2021
Journal Articles

Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium

Free
Kitsada Wudhikarn, Ana Alarcon Tomas, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Joseph P. McGuirk, Loretta Nastoupil, David L. Porter, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood
Blood (2021) 138 (Supplement 1): 2843.
https://doi.org/10.1182/blood-2021-150012
Published: 2021